EGFR and non-small cell lung carcinoma: Consistent with this notion, a more recent study analyzing tyrosine kinase inhibitor (TKI)-treated patients with EGFR-mutated NSCLC found very similar molecular profiles between de novo and secondary tumors, despite clinical differences similar to those observed between de novo and secondary stage IV LCNEC (41).